BUZZ-摩根大通将 Veeva 的评级上调至 "增持 "后,Veeva 的股价攀升

路透中文
Sep 08, 2025
BUZZ-<a href="https://laohu8.com/S/JPM">摩根大通</a>将 <a href="https://laohu8.com/S/VEEV">Veeva</a> 的评级上调至 "增持 "后,Veeva 的股价攀升

9月8日 - ** 医疗保健科技公司 Veeva Systems VEEV.N 股价盘前上涨 ~1.4% 至 276.7 美元

** 摩根大通将股票评级从 "中性 "上调至 "增持";将目标价从290美元上调至330美元

** 券商称其看好Veeva与IQVIA IQV.N(前身为IMS Health和Quintiles) 的合作及其使用Agentic人工智能(AI创造的新机遇。)

** 上个月,IQVIA 和 Veeva 宣布在 (link) 建立涵盖临床和商业领域的长期合作伙伴关系,并解决了所有悬而未决的争端。

** 券商称,Veeva与Salesforce CRM.N和其他软件供应商竞争,但其产品深度无人能及,尤其是在Vault CRM套件方面。

** 股票平均评级为 "买入";PT中位数为322美元--数据由LSEG编制

** 截至上次收盘,VEEV 今年已上涨约 30

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10